Rob Wilechansky
@WilechanskyMD
Followers
477
Following
2K
Media
1
Statuses
136
Transplant Hepatologist @OHSUGastro. Formerly @MGH_GI, @BMCimRES, and AASLD ELS. Grad of @ColumbiaPS and @WilliamsCollege. #Milanista 🔴⚫️
Portland, OR
Joined April 2019
📑 A natural language processing algorithm accurately classifies steatotic liver disease pathology to estimate the risk of #cirrhosis❕ #NLP #LiverTwitter #LiverX
1
12
18
Big news in the world of liver disease! The FDA has approved Elafibranor for patients with PBC. This is a huge step forward in the treatment of this chronic condition and offers new hope to those affected. #PBC #Elafibranor #FDAapproval
0
23
77
Hot off the press: Survodutide efficacy in#MASH including both MASH resolution & fibrosis improvement presented @EASLedu and published @NEJM today! @ArunJSanyalVCU @AlkhouriNaim @RamyYounes9 #livertwitter
2
18
95
Targeting MAP is crucial to hasten AKI recovery. See➡️ https://t.co/kVzX6A2GF6 by the mad genius @JoeCullaro Need more evidence? ➡️ https://t.co/e0CtbNQ5IK ➡️ https://t.co/MhiZDHxL0l
@AASLDtweets @ICA_Global_AKI @HrsHarmony
3
14
35
Big month for #MASLD trials - as we discuss costs of medications, nice to see the potential of low-cost alternatives. Congratulations to my favorite @traceyg_md (proud of you friend) and @WilechanskyMD @KathleenCoreyMD @DrLoomba @raychungmd @AndyChanMD @MGH_GI #livertwitter #mash
Randomized clinical trial compares use of low-dose aspirin vs placebo in reducing hepatic fat among adult patients with metabolic dysfunction–associated steatotic liver disease (MASLD) without cirrhosis. https://t.co/y3bUdoqlJa
0
4
19
Did you know about our new Fellows' Corner? Keeping up with an ever-evolving literature during GI and hepatology training is not an easy task. Here @WilechanskyMD discuss 3 papers with meaningful developments for diagnostics and therapeutics in hepatology! https://t.co/eN3IXhRuiI
0
3
15
Our DECEMBER ISSUE is live! Alcohol-related liver disease and MASLD, HCC surveillance, intestinal hormones, IBD, and much more! https://t.co/NbdzVS3w0C
2
22
50
Great to see the @LTxJournal & @HEP_Journal editorial fellows together at #TLM23 - @AlanLHutchison & @WilechanskyMD! 🔥 #livertwitter
0
5
21
While waiting for prohibitively expensive meds to be FDA approved for MASLD/MASH… this high-quality *RCT* demonstrated that 6 months of ASPIRIN reduced - Liver Fat❗️ - liver stiffness, liver enzymes, cT1❗️❗️ By: @traceyg_md @WilechanskyMD @KathleenCoreyMD @raychungmd
0
2
24
New episode! New host! We're ecstatic to welcome our new fellow lead #PatrickLee from @USC_KeckGILiver. Discussion is centered around finding a job, negotiation etc. We welcome back @WilechanskyMD to discuss what's new in @HEP_Journal. @LiverFellow @AASLDtweets
1
2
8
🆕REVIEW: Digital pathology and artificial intelligence in non-alcoholic steatohepatitis ➡️Current status and future directions. Read it here👉 https://t.co/69QDAgJz6J via @JHepatology #LiverTwitter
1
10
41
🚨 @AASLDtweets Practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis 🚨 JUST RELEASED https://t.co/52y1BQo0km
#LiverTwitter #LiverX
0
70
142
Hi! We were fortunate to spend time with @docamitgs to talk about the latest @AASLD HCC guidelines. In a new segment, we have @HEP_Journal editorial fellow @WilechanskyMD on to discuss outcomes from NASH clinical trial. @LiverFellow @UTSWNews 🍏:
podcasts.apple.com
Podcast Episode · Liver Talks: The Liver Fellow Network Podcast · 03/10/2023 · 49m
0
7
14
1/15 🤔Why does portal hypertension lead to splenomegaly. I also assumed the spleen became "congested" from backflow of blood. Turns out, it isn't that simple. And there are interesting therapeutic implications. Let's have a look.
7
274
1K
REVIEW‼️ Friedman S & Sanyal A. The future of hepatology: ✅Basic and translational science ✅Data management ✅Artificial intelligence ✅Precision medicine https://t.co/KfWfrOvtmJ
0
6
23
#HEP_highlight Saving Livers, One Blocker at a Time: A Bayesian Twist on CLD Management ✅Beta-blocker treatment is associated with a high probability of clinical benefit #LiverTwitter
https://t.co/hwfMqbzMTK
0
9
18
#HEP_highlights Before the biopsy: Accuracy of NITs in NAFLD patients with T2DM Pennisi G et al. LSM and AGILE 3+ individually or in sequential combination after FIB-4 or NFS have a similar good diagnostic accuracy for advanced fibrosis #LiverTwitter
https://t.co/4WVYE094Kw
1
8
15
A global action agenda for turning the tide on fatty liver disease in @HEP_Journal 🚨To implement this agenda, concerted efforts will be needed at the global, regional, and national levels. #LiverTwitter
https://t.co/DZheiC86aQ
1
12
32
Congratulations to our 2023 AASLD Foundation Award Recipients! 🎉Award recipients were selected from a highly competitive applicant pool, demonstrate an exceptional aptitude, and have a deep interest in #liver disease research and treatment. Read more at https://t.co/SfBmF4x3nM.
3
16
50
Newly published @HrsHarmony study: Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US - Journal of Hepatology https://t.co/3a0IMxrsj9
1
24
70